Interleukin-12 inhibits angiogenesis and growth of transplanted but not in situ mouse mammary tumor virus-induced mammary carcinomas

Cancer Research

Volumn 62, Issue 3, 2002, Pages 747-755

  Lee, James C ^a   Kim, David C ^a   Gee, Michael S ^a   Saunders, H Mark ^a   Sehgal, Chandra M ^a   Feldman, Michael D ^a   Ross, Susan R ^a   Lee, William M F ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; RECOMBINANT INTERLEUKIN 12;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER TRANSPLANTATION; CONTROLLED STUDY; FEMALE; MOUSE; MOUSE MAMMARY TUMOR ONCOVIRUS; NONHUMAN; PERICYTE; PRIORITY JOURNAL; TUMOR BLOOD FLOW; TUMOR VASCULARIZATION;

ANIMALS; CELL DIVISION; DISEASE MODELS, ANIMAL; FEMALE; INTERLEUKIN-12; MAMMARY NEOPLASMS, EXPERIMENTAL; MAMMARY TUMOR VIRUS, MOUSE; MICE; MICE, INBRED C3H; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; RECOMBINANT PROTEINS;

EID: 0036468547     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. What is the evidence that tumors are angiogenesis dependent?
2. Tumor-associated angiogenesis: Mechanisms, clinical implications, and therapeutic strategies
3. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma
4. 3 blocks human breast cancer growth and angiogenesis in human skin
5. Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: Novel concepts of angiostatic therapy from intravital videomicroscopy
6. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
7. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types
8. A simple procedure for the long-term cultivation of chicken embryos
9. Tumor growth and neovascularization: An experimental model using the rabbit cornea
10. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor
11. Mechanisms of angiogenesis
12. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF
13. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization
14. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF
15. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal
16. Interleukin- 12: A cytokine at the interface of inflammation and immunity
17. Interleukin-12: Basic principles and clinical applications
18. MMTV-induced mammary tumorigenesis: Gene discovery, progression to malignancy, and cellular pathways
19. Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome
20. Tumorigenesis by mouse mammary tumor virus: Proviral activation of a cellular gene in the common integration region int-2
21. Speculations on the role of ultraviolet radiation in the development of malignant melanoma
22. Tissue culture studies of mouse mammary tumor cells and associated viruses
23. Doppler ultrasound imaging detects changes in tumor perfusion during antivascular therapy associated with vascular anatomic alterations
24. Antitumor and antimetastatic activity of interleukin 12 against murine tumors
25. Systemic administration of rIL-12 induces complete tumor regression and protective immunity: Response is correlated with a striking reversal of suppressed IFN-γ production by antitumor T cells
26. Hypoxia-mediated apoptosis from angiogenesis inhibition underlies tumor control by recombinant interleukin 12
27. Interleukin-12 inhibits angiogenesis induced by human tumor cell lines in vivo
28. Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis
29. Permeability-related changes revealed at endothelial cell borders in inflamed venules by lectin binding
30. Tumor cell responses to IFNγ affect tumorigenicity and response to IL-12 therapy and antiangiogenesis
31. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production
32. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10
33. Activation of the STAT signaling pathway can cause expression of caspase 1 and apoptosis
34. Inhibition of angiogenesis in vivo by interleukin 12
35. Recombinant interleukin 12 enhances cellular immune responses to vaccination only after a period of suppression
36. Immune suppression by recombinant interleukin (rIL)-12 involves interferon γ induction of nitric oxide synthase 2 (iNOS) activity: Inhibitors of NO generation reveal the extent of rIL-12 vaccine adjuvant effect
37. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
38. Ability of systemic interleukin-12 to hamper progressive stages of mammary carcinogenesis in HER2/neu transgenic mice
39. Heterogeneous vascular dependence of tumor cell populations
40. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: Implications for antiangiogenic tumor therapies